Melflufen-dex proves active in multi-resistant MM

Print Friendly, PDF & Email


Paul Richardson, MD
Photo by Jen Smith
The combination of melflufen and dexamethasone demonstrated activity in patients with multi-resistant multiple myeloma (MM) in a phase 2 trial. Melflufen-dexamethasone produced an overall response rate of 33% in patients who had quad- or penta-refractory MM. The combination was considered well tolerated, although 13% of patients discontinued... [Read Article]
Print Friendly, PDF & Email

Ixazomib improves PFS after ASCT in MM

Print Friendly, PDF & Email


Sign announcing ASH 2018
©ASH/Rodney White 2018
Ixazomib improved progression-free survival (PFS) following autologous stem cell transplant (ASCT) in patients with newly diagnosed multiple myeloma (MM) in the TOURMALINE-MM3 trial. The oral proteasome inhibitor improved PFS by 39% compared to placebo. In addition, treatment with ixazomib was well tolerated, and there was a low... [Read Article]
Print Friendly, PDF & Email

Haplo-HSCT feasible in multiple myeloma

Print Friendly, PDF & Email


Micrograph showing MM
A retrospective study suggests haploidentical hematopoietic stem cell transplant (haplo-HSCT) is feasible in patients with multiply relapsed or high-risk multiple myeloma (MM). Investigators said haplo-HSCT produced an “acceptable” rate of non-relapse mortality (NRM)—21% at 1 year—in such patients. “Our results demonstrate that [haplo-HSCT] can be safely performed in appropriate patients with... [Read Article]
Print Friendly, PDF & Email

Triplet produces ‘unprecedented’ ORR in PI-refractory MM

Print Friendly, PDF & Email


Prescription drugs
Photo courtesy of the CDC
Phase 2 results suggest a three-drug regimen may improve response rates in patients with proteasome inhibitor (PI)-refractory multiple myeloma (MM). The combination—nelfinavir, bortezomib, and dexamethasone (NeVd)—produced an objective response rate (ORR) of 65% in this trial. In comparison, past studies have shown response rates of 24% to... [Read Article]
Print Friendly, PDF & Email

Triplet improves PFS in relapsed/refractory MM

Print Friendly, PDF & Email


Micrograph showing
multiple myeloma
Adding elotuzumab to pomalidomide and low-dose dexamethasone can improve progression-free survival (PFS) in patients with relapsed/refractory multiple myeloma (MM), according to the ELOQUENT-3 trial. These results support the recent U.S. approval of elotuzumab, pomalidomide, and dexamethasone in adults with MM who have received at least two prior therapies, including... [Read Article]
Print Friendly, PDF & Email

CAR T therapy for MM receives RMAT designation

Print Friendly, PDF & Email


Micrograph showing MM
P-BCMA-101, an autologous chimeric antigen receptor (CAR) T-cell therapy being developed to treat patients with relapsed/refractory multiple myeloma (MM), has received regenerative medicine advanced therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA). RMAT designation is intended to expedite the development and review of regenerative medicines that are intended to... [Read Article]
Print Friendly, PDF & Email

Molecule enhances PI activity in multiple myeloma

Print Friendly, PDF & Email


Theoretical binding
of E64FC26 to PDI
Image from Reeder
Robinson of MUSC
Researchers say they have identified a new class of protein disulfide isomerase (PDI) inhibitors that sensitize multiple myeloma (MM) cells to proteasome inhibitors (PIs). The investigators screened approximately 20,000 compounds spanning multiple chemical libraries and found the compound E61 to be a “striking... [Read Article]
Print Friendly, PDF & Email